Literature DB >> 27882408

[Evidence-based recommendations on diagnostics and therapy of axial spondyloarthritis : S3 guidelines of the German Society of Rheumatology (DGRh) in cooperation with the Association of the Scientific Medical Societies in Germany (AWMF)].

U Kiltz1, M Rudwaleit2, J Sieper3, J Braun4.   

Abstract

The clinical course of axial spondyloarthritis (SpA) is variable and characterized by chronic back pain and extraspinal manifestations, such as asymmetrical arthritis, dactylitis and enthesitis. Extra-articular manifestations in the eyes (anterior uveitis), skin (psoriasis) and intestines (chronic inflammatory bowel disease) are also frequent manifestations in patients with SpA. Due to the heterogeneity of disease manifestations and the partial concentration on structural alterations in the sacroiliac joints visible in X‑ray images, the diagnosis is often delayed for many years. An important step in the direction of improved early recognition of axial SpA was establishment of the Assessment of SpondyloArthritis International Society (ASAS) classification criteria published in 2009, which focused on the initally deep-seated back pain and chronicity in relatively young patients as well as the importance of magnetic resonance imaging and HLA B 27 determination in the early stages of the disease. In order to achieve the foundations for an effective and timely therapy of affected patients, in 2014 on the initiative of the German Society of Rheumatology, S3 guidelines on axial SpA including Bechterew's disease and early forms were formulated in cooperation with other specialist societies. This article gives an overview of the contents of the S3 guidelines on axial SpA.

Entities:  

Keywords:  Ankylosing spondylitis; Dactylitis; Enthesitis; Magnetic resonance imaging; Management

Mesh:

Year:  2017        PMID: 27882408     DOI: 10.1007/s00393-016-0232-x

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  30 in total

1.  Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.

Authors:  A Spoorenberg; D van der Heijde; E de Klerk; M Dougados; K de Vlam; H Mielants; H van der Tempel; S van der Linden
Journal:  J Rheumatol       Date:  1999-04       Impact factor: 4.666

2.  Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

Authors:  Dominique Baeten; Joachim Sieper; Jürgen Braun; Xenofon Baraliakos; Maxime Dougados; Paul Emery; Atul Deodhar; Brian Porter; Ruvie Martin; Mats Andersson; Shephard Mpofu; Hanno B Richards
Journal:  N Engl J Med       Date:  2015-12-24       Impact factor: 91.245

3.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.7 Rehabilitation].

Authors:  U Kiltz; W Mau; U Repschläger; E Böhle; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

4.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 6 Diagnostics].

Authors:  U Kiltz; M Rudwaleit; J Sieper; D Krause; K-G Hermann; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

5.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 9 International classification of functioning, disability and health (ICF)].

Authors:  U Kiltz; W Mau; U Repschläger; E Böhle; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

6.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8 Therapy, 8.1 Treatment concept, 8.2 Therapy targets and strategy].

Authors:  U Kiltz; J Sieper; M Rudwaleit; H Kellner; D Krause; E Böhle; H Böhm; W-H Böhncke; J-F Chenot; A Heiligenhaus; S Jaresch; W Mau; U Oberschelp; U Pleyer; U Repschläger; E Schneider; U Smolenski; A Stallmach; M Stemmer; B Swoboda; C Ulrich; M Winking; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

7.  Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers.

Authors:  A Zink; J Braun; J Listing; J Wollenhaupt
Journal:  J Rheumatol       Date:  2000-03       Impact factor: 4.666

8.  Prevalence of vertebral fractures by semiautomated morphometry in patients with ankylosing spondylitis.

Authors:  Nuria Montala; Xavier Juanola; Eduardo Collantes; Elisa Muñoz-Gomariz; Carlos Gonzalez; Jordi Gratacos; Pedro Zarco; Jose Luis Fernandez Sueiro; Juan Mulero; Juan Carlos Torre-Alonso; Enrique Batlle; Loreto Carmona
Journal:  J Rheumatol       Date:  2011-03-01       Impact factor: 4.666

9.  ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health.

Authors:  A Boonen; J Braun; I E van der Horst Bruinsma; F Huang; W Maksymowych; N Kostanjsek; A Cieza; G Stucki; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

10.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

View more
  5 in total

Review 1.  [Rheumatological care in the Rheumazentrum Ruhrgebiet Rheumatism Center-a model for conurbations].

Authors:  J Braun; U Kiltz; I Andreica; B Buehring; B Guminski; U Häusler; H Kavruk; D Kiefer; R Lochowski; B Mintrop; X Baraliakos
Journal:  Z Rheumatol       Date:  2019-10       Impact factor: 1.372

2.  Evaluation of a special concept of physical therapy in spondyloarthritis: German multimodal rheumatologic complex treatment for spondyloarthritis.

Authors:  Philipp Klemm; Ole Hudowenz; Thomas Asendorf; Gabriel Dischereit; Ulf Müller-Ladner; Uwe Lange; Ingo H Tarner
Journal:  Clin Rheumatol       Date:  2020-01-08       Impact factor: 2.980

Review 3.  [Improved early diagnostics of rheumatic diseases : Monocentric experiences with an open rheumatological specialist consultation].

Authors:  A Voigt; E Seipelt; H Bastian; A Juche; A Krause
Journal:  Z Rheumatol       Date:  2018-11       Impact factor: 1.372

Review 4.  Multidisciplinary working in the management of axial and peripheral spondyloarthritis.

Authors:  Tania Gudu; Deepak R Jadon
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-10       Impact factor: 5.346

Review 5.  [Treatment of rheumatoid arthritis and spondylarthritis with biologics].

Authors:  Christoph Fiehn
Journal:  Internist (Berl)       Date:  2022-01-14       Impact factor: 0.743

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.